Hosted on MSN22d
From pills to new uses, here's what Eli Lilly’s top scientist sees as the future of weight loss drugsEli Lilly Chief Scientific Officer Dan Skovronsky said newer obesity medicines need to deliver more than just weight loss to compete with Zepbound and Wegovy. The development of pills and more ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Indianapolis Star on MSN16d
Eli Lilly will build 4 new manufacturing sites to increase domestic drug productionEli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants ...
Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.
Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...
Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” fourth quarter 2024 investor ...
Dan Skovronsky knows what makes a good obesity drug. As chief scientific officer at Eli Lilly, he's already done it once with the company's weekly shot, Zepbound. He's trying to do it again with a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback